Memory-like differentiation, tumor targeting monoclonal antibodies, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer.
Miriam T JacobsPamela WongAlice Y ZhouMichelle Becker-HapakNancy D MarinLynne MarsalaMark FosterJennifer A FoltzCelia C CubittJennifer TranDavid A Russler-GermainCarly NealSamantha Kersting-SchadekLily ChangTimothy SchappePatrick PenceEthan McClainJose P ZevallosJason T RichRandal C PanielloRyan S JacksonPatrik PipkornDouglas R AdkinsCarl J DeSelmMelissa M Berrien-ElliottSidharth V PuramTodd A FehnigerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
These pre-clinical findings demonstrate that ML differentiation alone or coupled with either cetuximab-directed targeting or EphA2 CAR engineering were effective against HNSCCs and provide the rationale for investigating these combination approaches in early phase clinical trials for HNSCC patients.